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Research highlights
Scientific benefits:
•    Acquisition of pharmacodynamics dose-responses increases 
sensitivity 
•    Platelet function is assessed directly
3Rs benefits:
•    Procedures are conducted at a lower severity level avoiding 
pain and suffering
•    Animal numbers are reduced by 85%
Practical benefits:
•    Simplistic alternative micro-sampling approaches are 
available that require only standard laboratory equipment and 
minimal training
Current applications:
•    Investigating cardiovascular risk associated with exposure to 
airborne pollution and HIV/antiretroviral therapy
Future applications:
•    Broadly within the fields of anti-thrombotic therapy and 
platelet physiology/pharmacology 
•    Potential for further reduction in the field by developing flow 
cytometric approaches for multiple analyses of diluted  
micro-samples
Cardiovascular diseases and platelets
Cardiovascular diseases including myocardial infarction (MI) and 
stroke are the major cause of death in Western society. Cardio-
vascular risk is heightened by the unavoidable risk factor of age, 
but is also driven by avoidable, or potentially avoidable, factors 
such as smoking, poor diet and airborne pollution1. Cardiovascular 
disease is also increasingly important to clinicians and scientists 
in other fields. For example, cardiovascular events are the major 
cause of death in people living with HIV who are virally supressed 
by antiretroviral therapy2.
When investigating mechanisms of cardiovascular disease, 
platelets are of obvious interest. Platelets are circulating blood 
elements with central roles in haemostasis and thrombosis and 
are a major therapeutic target in the treatment of arterial throm-
botic events such as MI. Aspirin and clopidogrel inhibit platelet 
activation and are widely prescribed in patients following MI, 
although their efficacy remains suboptimal and new therapeutic 
approaches are required.
When activated, platelets undergo a series of signalling proc-
esses involving calcium release and the expression of activa-
tion markers, including P-selectin, on the extracellular surface. 
Platelets also release a range of inflammatory mediators from 
intracellular granules, including chemokines such as PF4 (Platelet 
Factor 4) and CCL5 (chemokine (C-C motif) ligand 5). Platelets 
therefore generate a range of signals that drive processes such as 
adhesion, aggregation and inflammation. Human platelets are 
easily isolated from blood and their function may be assessed 
through a range of established assays. The gold-standard functional 
assay remains light transmission aggregometry, which measures 
increases of light transmission through initially opaque platelet 
suspensions as platelets aggregate3.
In vitro and ex vivo analysis of platelet function
Platelets are anucleate and it is not possible to alter protein 
expression using traditional in vitro strategies, such as siRNA 
knockdown. Therefore, it is often necessary to employ mouse 
models where protein expression of the precursor cell, the meg-
akaryocyte, can be altered. A significant reduction achievement 
concerning in vitro mouse platelet aggregometry has been the 
development of 96-well plate light transmission approaches4, 
which use much smaller plasma volumes than conventional 
cuvette approaches. By reducing the standard plasma volume 
from 450 to 90 μl, a reduction in mouse use of 80% is possible 
when switching to a 96-well format. In addition, running 
multiple samples in parallel in a 96-well plate, rather than con-
secutive cuvette analyses, can reduce sample variability and thus 
reduce numbers of animals required per experiment.
Flow cytometry is widely used in biomedical research and with 
an increasing number of available antibodies and markers that 
permit diverse analysis in very small samples of cells and fluids, 
this approach can dramatically increase the number of experi-
mental parameters per experiment. Platelet researchers routinely 
monitor high affinity integrin αIIbβ3, alpha and dense granule 
release as markers of platelet activation alongside assays to deter-
mine changes of Ca2+ signalling and aggregation5–8. Emergent 
flow cytometers, such as the BD Accuri C6, enable agonists to 
be added during sample acquisition, allowing for simultaneous 
kinetic evaluation of platelet activation8. A major advantage of this 
technology is that data can be obtained with diluted samples (i.e. 
1:200), raising the possibility that micro-sampling could replace 
alternative blood collection techniques, such as retro-orbital 
sampling and cardiac puncture. Ongoing work in our laboratory 
is evaluating the potential of using flow cytometry to perform 
ratiometric analysis of agonist-evoked calcium signalling, plate-
let aggregation and protein studies using human samples. If 
successful, these techniques could be applied to mouse studies 
and reduce the overall number of animals required.
Reporting of numbers of animals used per experiment in the 
literature is highly variable and it is often not possible to deter-
mine whether the same animal has been used in multiple assays. 
Taking these limitations into account, we predict that measure-
ment of platelet activation markers, aggregation response and 
calcium response to three platelet agonists using conventional 
assays would require 13 mice per experimental replicate. How-
ever, development of flow cytometric approaches discussed here 
could reduce this number by over 90%.
Need for animal models
The involvement of multiple cell types and tissues in the etiology 
of cardiovascular diseases creates a strong necessity for animal 
studies, and more than 63,000 animal procedures involving mice 
were reported in the Cardiovascular, Blood and Lymphatic field 
by the UK Home Office in 2016 (https://www.gov.uk/government/
statistics/statistics-of-scientific-procedures-on-living-animals-
great-britain-2016).
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Within the field of thrombosis and platelets, vascular injury 
models involving endothelial damage via chemical, laser or 
mechanical trauma and subsequent thrombus formation are widely 
used9. Although the technique is conducted terminally under 
general anaesthesia, the number of thrombi that can be recorded 
per animal is limited, since, for example, both carotid arteries 
cannot be ligated. In addition, the high variance of the data 
outputs mean that relatively high numbers of animals are required 
to statistically power studies. Efforts are currently underway 
to develop an ex vivo carotid artery model involving luminal 
cannulation of excised artery sections: https://www.nc3rs.org.uk/
reducing-animal-use-thrombosis-research-ex-vivo-injury-model. 
In due course, it is hoped that this model will reduce mouse use 
by at least 50% since both carotid arteries can be used.
The vascular endothelium releases mediators such as nitric oxide 
(NO) and prostacyclin, which inhibit platelet function and are 
central to both haemostasis and the development of platelet-driven 
cardiovascular events10–12. Vascular injury models have proven 
to be problematic when used to assess the impact of endothelial 
mediators in platelet-driven thrombosis. In the NO field, abla-
tion of endothelial NO synthase (eNOS) was shown to result 
in no phenotype13,14, an anti-thrombotic phenotype15,16 or a pro- 
thrombotic phenotype17 by different groups using similar 
experimental approaches. Assessment of the role of endothe-
lial mediators requires, rather than a vascular injury approach, 
a model in which platelets circulate freely in the context of a 
functional vascular endothelium, which can be manipulated 
pharmacologically or genetically18.
Animal models: Need for refinement
The need to model platelet function and thrombosis in vivo has 
led to the development of vascular injury models, which are con-
ducted under general anaesthesia, but also to the use of models of 
thromboembolic mortality, which are conducted in conscious ani-
mals and, as the name suggests, use mortality as an end-point19. 
Thromboembolic mortality models allow the assessment of platelet 
aggregation in vivo against the backdrop of a functional vascular 
endothelium. Mortality models involve the intravenous injection 
of thrombogenic agents such as collagen or thrombin with death 
or hind limb paralysis as an end-point. To quote from a 2003 
publication20: “Pulmonary embolism was induced in male Swiss- 
Webster mice by intravenous tail injection of a mixture of colla-
gen and epinephrine. Doses were selected that resulted in death or 
at least 15 minutes of hind-limb paralysis in approximately 90% 
of control mice”. The effects of genetic modification or drug 
action are measured by their ability to significantly change the 
proportions of mice killed or paralysed. This model has been 
used relatively recently to assess the roles of novel intracellular 
signalling pathways in platelets21, endogenous compounds22, 
platelet receptor antagonists23, free radical scavengers24, dietary 
compounds25, endogenous nitric oxide10 and a novel aspirin 
derivative26 on thromboembolic mortality.
Induction of thromboembolism in mice undoubtedly inflicts con-
siderable pain and suffering. Following injection, the mice adopt 
a hunched posture, become immobile and breathing becomes 
laboured19. The mice remain in this state until they die or are 
assessed, by their inability to use their hind-limbs, to be paralysed. 
The rationale for conducting the procedure in conscious mice is 
that under anaesthetic, mortality is more difficult to induce19 (pre-
sumably shock contributes to death and blood pressure is lower 
under anaesthesia) and paralysis cannot easily be determined. 
In addition to the severe impact upon the animals, this technique 
requires large numbers of subjects and studies have been published 
involving 20 or 40 animals per experimental group10,27, so that 
the total number in a publication can run into the hundreds.
Refined model development
We have developed refined models for the assessment of plate-
let thromboembolism using monitoring of radiolabelled platelets 
in anaesthetised mice28,29. Our technique avoids the use of death as 
an end-point and instead measures the thromboembolic response 
in real-time by tracking radiolabelled platelets via externally 
placed scintillation probes28. To achieve this, mice are terminally 
anaesthetised and bled by cardiac puncture, platelets are radiola-
belled with a gamma emitter and then infused into a second ter-
minally anaesthetised mouse. Thus, a model is created in which 
radiolabelled platelets circulate freely against the background 
of a fully functional vascular endothelium, and so retaining 
a key feature that has been used historically to justify the use of 
thromboembolic mortality models. The same range of thrombo-
genic substances that can be used to induce mortality, when given 
at lower doses, induce reversible and dose-dependent increases 
in platelet counts in a probe suspended over the pulmonary 
vascular bed. Thus, the whole time course of the platelet throm-
boembolic response may be recorded and quantified in a number 
of ways, including peak response and area under the curve28. We 
were able to validate our model with the anti-platelet drug 
aspirin as a means of assessing its potential clinical relevance28.
Reduction
Despite the fact that real-time monitoring requires animals both 
for acquisition of platelets and monitoring, our approach allows 
not only refinement of procedures to a lower severity level, but has 
also reduced the numbers of animals required in a typical experi-
ment. The extent of reduction is best exemplified when looking at 
work demonstrating the role of endogenous NO in inhibiting 
platelet activation in vivo. This was first demonstrated in mice in 
1998 when administration of a NO synthase inhibitor was shown to 
increase thromboembolic mortality in mice10. This paper required 
the use of 200 mice to demonstrate the antithrombotic activ-
ity of endogenous NO and additional studies (including in vivo 
studies in other species) to link mortality studies with a plate-
let-mediated effect. A comparable study using refined real-time 
platelet monitoring involved only 30 mice with all procedures 
performed under general anaesthesia (classified as non-recovery 
severity level under current Home Office legislation). Thus the 
refined model led to an 85% reduction in mouse use in a typical 
experiment18.
Scientific application of refined model
Real-time platelet monitoring produces dynamic and quantifi-
able read-outs and provides dose-dependent platelet accumulation 
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responses. This contrasts with mortality studies which simply 
measure the occurrence, or lack of, an event. The refined model 
should therefore provide greater sensitivity since we are able 
to detect shifts in pharmacodynamic dose-responses, reflecting 
either enhanced or reduced platelet activation. We suggest that 
recent work in the field of cardiovascular risk in the context of 
airborne pollution demonstrates this30,31. It has been known for 
many years that exposure to pollution leads to increased cardio-
vascular morbidity and mortality and, in particular, exposure to 
particulate pollution increases myocardial infarction, a platelet-
driven cardiovascular event32. Due to their physicochemical prop-
erties, combustion-derived nanoparticles such as diesel exhaust 
particles (DEP) have been strongly implicated in driving cardio-
vascular risk33. DEP have been shown to induce inflammation34 
and due to their nanoparticulate nature are hypothesised to trans-
locate across the pulmonary epithelial barrier into the blood35, 
which would bring them into direct contact with circulating 
platelets. Having shown that DEP can interact physically with 
platelets and induce their aggregation in in vitro human studies30, it 
was necessary to proceed to in vivo studies to translate this finding 
to a more relevant whole organism setting. It was shown that both 
introduction of DEP to circulating blood to mimic translocation30 
and tracheal instillation of DEP to mimic inhalation31 resulted in 
a significantly enhanced platelet thromboembolic response at 
doses of DEP that reflected human exposure levels. These studies 
contributed to the now more widely accepted thinking that DEP 
exposure may enhance cardiovascular risk in the human popula-
tion and provided a potential mechanism. We suggest that this 
type of work, which highlights relatively subtle events that require 
sensitive models, would not have been possible in mortality mod-
els, certainly not at doses of DEP that were relevant to human 
exposure levels.
Dissemination and uptake
3Rs benefits of animals arise not from their development, which 
creates potential, but from their subsequent employment in 
studies where non-refined models would have been used in the 
absence of refined alternatives. Examples from our own group 
have been discussed above and there are other outcomes in the 
fields of nanotoxicology36, nutritional biochemistry37 and calcium 
signalling38. We have also collaborated with other groups in the 
fields of cyclooxygenase pharmacology12, integrin linked kinase8 
and sulforophane (an isothiocyanate with potential antithrom-
botic activity; unpublished study, authors: Gillespie, Holloway, 
Becker, Rauzi, Vital, Shreveport, Taylor, Stokes, Emerson and 
Gavins).
The ultimate aim of 3Rs research is broad uptake of emerging 
3Rs technologies by the scientific community and a consequen-
tial reduction in the use of non-refined procedures. Quantification 
of continued use of thromboembolic mortality models is dif-
ficult since their use is often obscured through lack of inclusion 
in abstracts and use of vague terminology. PubMed searches 
of [thromboembolism + mouse] and [thrombosis + mortality + 
mouse] and [platelet + mortality + mouse], followed by a manual 
search to identify publications revealed more than 50 papers where 
thromboembolic mortality was used in 2013. A review of these 
papers found that all used mortality and/or paralysis as end-points, 
the duration of the experiments varied from 5 minutes to 96 hours, 
and experimental groups varied from 10 to 30 mice, with 10 to 
360 mice used in total in each paper. Similar numbers of papers 
appear in the 5 years preceding 2013.
More recently, in 201639, we sampled 9 peer review articles 
using models of thromboembolic mortality and found between 
3 and 40 animals per experimental group, with some studies not 
reporting animal use, the duration of the period in which animals 
were observed following induction of thromboembolism var-
ied from 5 min to 5 days. Anaesthesia of any sort was only used 
in one study. Unfortunately, thromboembolic mortality models 
are therefore still used despite the availability of an alternative 
refined model. Potential reasons for continued use of thromboem-
bolic mortality models are: Lack of awareness of alternatives, 
animal welfare not a primary consideration, inability to work 
with radioisotopes, lack of expertise and preference for 
collaboration rather than establishment of new technologies
Increasing awareness of the 3Rs and refined models is an 
ongoing endeavour and we continue to work collaboratively. In 
addition, we set out to develop refined methods to study platelet 
thromboembolism in vivo that could be more widely adopted since 
they could be conducted with minimal training, non-specialised 
equipment and at low cost. We have now developed a model that 
allows thromboembolism to be assessed by measuring the fall 
in circulating platelets that occurs during thromboembolism in 
blood microsamples39. Microsamples are taken from the tail vein 
of anaesthetised mice and repeated sampling allows for counts 
to be measured before and during the thromboembolic response 
in an individual animal. This technique allows thromboembolism 
to be assessed without the need for specialised equipment and 
without radioisotopes.
Conclusions
In conclusion, platelet function can now be assessed in vitro and 
in vivo using 3Rs approaches that reduce the severity level and 
also the numbers of animals used in procedures. Thromboembolic 
mortality approaches should now be considered obsolete, since 
even where the gold-standard real-time monitoring technique 
cannot be employed, more simplistic assays can be used without 
the need for radioactive material or complex procedures.
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